CAPONE: Adverse Childhood Experiences, Adaptation and Breast Cancer

Sponsor
University of Lorraine (Other)
Overall Status
Recruiting
CT.gov ID
NCT05843539
Collaborator
Ligue contre le cancer, France (Other)
128
1
19.6
6.5

Study Details

Study Description

Brief Summary

Adverse Childhood Experiences (ACEs) have long been linked to mental health problems in adulthood. In the case of cancer, no study has considered that such an anteriority could make patients more vulnerable emotionally, even though the presence of reactionary disorders such as stress, anxiety or depression are characteristic of such a pathology. Activated during periods of stress and therefore during the illness, even the attachment system is mobilized and must be considered to allow more understanding of the illness experience. The attachment style can be seen here as an individual dimension that plays a role in the emotional regulation and resilience of patients. It is also particularly solicited during the remission phase, a complex and singular period of cancer disease that confronts patients with an ambivalence of hope and fear. The fear of recurrence is a concern that the cancer may return or progress in the same organ or in another part of the body. This is a determining factor in the occurrence of anxiety-depressive disorders. Finally, several studies have shown a strong association between depression/anxiety and Cancer-Related Fatigue (CRF) after treatment, especially during the remission phase.

ACEs leave physiological and epigenetic impact that can nowadays be easily evaluated, thus providing additional evidence between adversity, physiological and epigenetic vulnerability and the ability to adapt to life's challenges such as cancer. Life history changes are mediated by changes in cellular mechanisms affecting genome expression. It is currently widely demonstrated that ACEs increases epigenetic modifications.

The interest of this project is therefore to highlight the psychological consequences related to the occurrence of cancer in the developmental history (in terms of adversities) of patients who have completed adjuvant chemotherapy for breast cancer, taking into account the patients' previous attachments, resilience, fear of recurrence and perceived fatigue in order to consider their interactions and their effects on their psychological health and ultimately on their quality of life.

Condition or Disease Intervention/Treatment Phase
  • Genetic: Biological and epigenetic measures

Study Design

Study Type:
Observational
Anticipated Enrollment :
128 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Adverse Childhood Experiences, AdaPtatiOn and Breast Cancer
Actual Study Start Date :
Apr 12, 2022
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Outcome Measures

Primary Outcome Measures

  1. Quality of life of women in remission from breast cancer [Baseline. Through study completion, an average of 1 year.]

    The primary outcome was quality of life assessed with the Short Form Survey 12 (SF-12 scale). The score ranges from 0 to 100, with a score above 50 indicating average quality of life, 40 to 49 indicating mild disability, 30 to 39 indicating moderate disability, and below 30 indicating severe disability.

Secondary Outcome Measures

  1. Fear of recurrence [Baseline. Through study completion, an average of 1 year.]

    The level of fear of cancer recurrence as assessed by the Cancer Recurrence Fear Inventory

  2. Fatigue [Baseline. Through study completion, an average of 1 year.]

    Level of fatigue assessed by the Multidimensional Fatigue Inventory (MFI). It is a questionnaire with 20 items on a 5-point likert scale ranging from 1 "strongly disagree" (worth 1 point) to 5 "strongly agree" (worth 5 points). The score is calculated by summing the points on the scale. The higher the score, the more severe the fatigue.

  3. Anxiety and Depression [Baseline. Through study completion, an average of 1 year.]

    Level of anxiety and depression assessed using the Hospital Anxiety and Depression Scale (HADS). This scale evaluates the level of anxiety in 7 items and the level of depression in 7 items, ranging from 0 to 3. A score greater than or equal to 10 indicates a definite level of anxiety or depression.

  4. Attachment [Baseline. Through study completion, an average of 1 year.]

    Attachment relationships were assessed using the Relationship Scales Questionnaire (RSQ).

  5. Adverse Childhood Experiences [Baseline. Through study completion, an average of 1 year.]

    The number of adverse childhood and adolescent experiences assessed using the Adverse Childhood Experiences International Questionnaire (ACE-IQ). The total number of ACEs to which the participant has been "exposed" is summed to create an ACE score ranging from 0 (no ACEs) to 13. A score of 0 ACEs means a low level of adversity and a score of 13 means a major level of adversity.

  6. Resilience [Baseline. Through study completion, an average of 1 year.]

    The level of resilience estimated using the Brief Resilience Scale (BRS). The Brief Resilience Scale is a 6-item questionnaire. Each item is rated on a 5-point Likert scale. Higher scores indicate greater resilience.

  7. RMSSD values [Baseline. Through study completion, an average of 1 year.]

    Differences in resting RMSSD (root mean square of successive differences between normal heartbeats) values according to the status with or without ACE, performed via the Caducy (software)

Other Outcome Measures

  1. Stress measurement [Baseline. Through study completion, an average of 1 year.]

    Hair cortisol levels via analysis of 100 hairs collected with the root and stored at 4°C

  2. Measurement of epigenetic methylations in relation to childhood adversity [Baseline. Through study completion, an average of 1 year.]

    Percentage methylation of genes coding for directed analysis of target regions coding for NR3C1 and FKBP5 genes derived from whole blood, saliva and oral cells assessed using chromatin immunoprecipitation (ChIP) assays

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Have had breast cancer

  • Be considered in remission

  • Be over 18 years of age

  • Literate (able to understand the information and complete the questionnaire independently)

  • Agree to participate in the project and sign the informed consent form

Exclusion Criteria:
  • Be a person subject to a legal protection measure

  • Be a protected adult, under guardianship or curators

  • Be undergoing oncological treatment

  • Have a lack of autonomy making it impossible to complete the questionnaire online

  • Have had or have begun psychotherapeutic treatment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ur 4360 Apemac Metz Lorraine France 57000

Sponsors and Collaborators

  • University of Lorraine
  • Ligue contre le cancer, France

Investigators

  • Principal Investigator: Marion Trousselard, Pr, UR 4360 APEMAC, University of Lorraine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christine Rotonda, Director of the research pole in Pierre Janet Center, University of Lorraine
ClinicalTrials.gov Identifier:
NCT05843539
Other Study ID Numbers:
  • 2021-A02850-36
First Posted:
May 6, 2023
Last Update Posted:
May 6, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Christine Rotonda, Director of the research pole in Pierre Janet Center, University of Lorraine
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 6, 2023